Articles tagged with Cancer Patients
Researchers at the University of Leipzig Medical Center have identified biomarkers associated with the response to CAR T cell therapy in multiple myeloma. These biomarkers enable patients to predict their likelihood of responding well or less well to treatment before initiating therapy.
A new study by the American Cancer Society found that cancer survivors reporting loneliness experience a higher mortality risk compared to those with low or no loneliness. The study identified a dose-response association between loneliness levels and mortality risk, with the highest risk among those experiencing severe loneliness.
Researchers at TUM have uncovered a mechanism by which tumor cells prevent the formation of immune responses, including cytotoxic T cells. This discovery provides rationales for new cancer immunotherapies and could enhance existing treatments.
MIT engineers have developed a closed-loop drug-delivery system that can improve chemotherapy outcomes by continuously monitoring patients and adjusting dosage. The new system, called CLAUDIA, uses commercially available equipment to analyze blood samples every five minutes and adjust infusion rates in real-time.
A new study published in the Journal of Clinical Oncology identified NECTIN4 amplification as a potential genomic biomarker for predicting treatment response to enfortumab vedotin in patients with advanced urothelial carcinoma. The study found that over 90% of patients with NECTIN4 amplification showed tumor response to EV therapy.
A new study by the American Cancer Society highlights the financial impact of a cancer diagnosis on working-age adults, leading to employment disruptions and loss of household income. Nearly 60% of working-age cancer survivors report at least one type of financial hardship.
Patients who quit smoking before starting chemotherapy or radiation responded better to treatment, were less likely to need their voice boxes surgically removed, and lived significantly longer than those who continued to smoke. Quitting smoking also improved quality of life for seven years after treatment.
The FDA has approved the use of N-803, an immunotherapy drug, in combination with BCG for treating patients with non-muscle invasive bladder cancer who did not respond to conventional treatment. The approval is based on a trial led by UCLA's Dr. Karim Chamie, which showed improved outcomes and longer overall survival rates.
A new clinical trial reveals that a novel writing therapy can significantly reduce cancer-related trauma, depression, anxiety, and hopelessness in late-stage cancer patients. By confronting their greatest fears through written exposure-based coping (EASE), participants experience improved mental well-being.
A new AI-based approach, PERCEPTION, uses single-cell transcriptomics to predict patient response to cancer drugs and monitor resistance. The approach was validated in three clinical trials for multiple myeloma, breast, and lung cancer, with promising results.
Researchers discovered that mutations in noncoding regions of cancer-driving genes can alter mRNA abundance, leading to increased or decreased protein production. This discovery may lead to the development of prognostic testing tools and a better understanding of gene regulation mechanisms in cancer progression.
The innovative Integrated Virtual Care (IVC) program successfully connected residents with family physicians in Renfrew County, addressing the rural shortage of primary care providers. Over 2,800 unique patient appointments were conducted, with 70% done virtually, offering comprehensive team-based primary care.
A national cohort study found that neighborhood disadvantage was independently associated with shorter breast cancer–specific survival. The study suggests potential unaccounted-for mechanisms, including both nonbiologic and biologic factors, and highlights the need for further research.
Only 4% of cancer survivors met all four American Cancer Society guidelines, with a mean of 2.0 guidelines met. This study aims to improve understanding of guideline adherence and inform recommendations for patients who have completed cancer treatments.
A study by the University of Gothenburg found that women with triple-negative breast cancer and high immune cell levels have a lower relapse risk after surgery. This suggests that these patients may not need chemotherapy, despite having faster-growing tumors and higher relapse rates than other breast cancers.
Researchers at the University of Pittsburgh have discovered how to overcome resistance to conventional immunotherapies in metastatic uveal melanoma. They developed a clinical tool called Uveal Melanoma Immunogenic Score (UMIS) to predict patient response and improve treatment outcomes.
A new study developed two machine learning models to quantify CD8+ cell positivity and classify the immunophenotype of cancer specimens in patients with non-small cell lung cancer. The models hold promise for identifying patients who may benefit from immunotherapy.
The PRECEDE study found that nearly 80% of participants in the highest-risk cohort completed baseline imaging, highlighting the feasibility of improving early detection and prevention for pancreatic cancer. Researchers recommend sorting individuals into three groups based on family history and genetic mutations to tailor surveillance.
A new Lancet Commission reveals that many people with breast cancer are being systematically left behind due to inaction on inequities and hidden suffering. The commission highlights the need for better patient support, including improved communication between patients and healthcare professionals.
Researchers have developed a new treatment that uses tailored doses of anti-cancer drugs released directly into the surgical cavity to treat liver cancer. The approach has shown promise in reducing recurrence rates and minimizing chemotherapy side effects, with potential applications for other types of cancer.
A groundbreaking treatment approach that combines genetic testing with individualized drug testing on tumor samples has shown promising results in treating relapsed pediatric cancer patients. The study achieved an impressive 83% improvement rate, including Logan Jenner's successful treatment after his leukemia relapse.
The NCCN 2024 Annual Conference shared updates on improving cancer care worldwide, including plenary sessions on drug shortages and hereditary cancer risk. Key takeaways include the need for transparency around oncology supply chains and the importance of genetic testing to reduce cancer risk.
A new study found that survival rates after hip or spine fractures are comparable to or worse than those seen in patients with certain types of cancer. The study, which analyzed data from over 100,000 Canadians aged 65 and older, highlights the urgent need for secondary prevention interventions before hospital discharge.
A study of 12 patients with sinonasal mucosal melanoma found that brisk tumor-infiltrating lymphocytes associated with improved outcomes, while anti-PD-L1 therapy showed potential as a therapeutic strategy. Further research is needed to confirm these findings.
A 10-minute virtual reality session significantly lessened pain in hospitalized patients with cancer, with sustained benefits even a day later. The study found that VR sessions had a greater impact than guided imagery, improving not only pain severity but also related issues like general distress.
A pilot study by UCLA Health investigators suggests that treating patients with immunotherapy and chemotherapy before surgery may improve long-term outcomes for those with borderline resectable pancreatic cancer. The study found a higher rate of successful tumor removal and increased overall survival when compared to historical controls.
A phase 2 study by Dana-Farber Cancer Institute investigators found notable activity in pre-treated patients with a difficult-to-treat form of endometrial cancer, including six out of 16 patients experiencing tumor reduction. The combination of mirvetuximab soravtansine and pembrolizumab met its primary endpoint and showed promise for ...
MD Anderson researchers presented studies on combination therapies for AML and lung cancer, tumor microbiomes in immunity, and improved HPV screening. Genetic markers predict extended survival with KRAS inhibitors and may identify patients who benefit from novel combinations.
A large trial enrolling nearly 2,800 patients from five countries has clarified the situation for patients with larger metastases. The study found that leaving most of the lymph nodes intact resulted in similar recurrence rates as completion axillary dissection, but with fewer arm-related complications.
Researchers at the University of Cincinnati Cancer Center presented abstracts on new potential drugs and targets for treating various types of cancer. A study found that a brain-permeable drug called AM-101 sensitizes brain metastatic tumors to radiation, improving survival in preclinical animal models.
A new study by Fred Hutchinson Cancer Center found that 21.9% of people with cancer participate in some form of clinical research, including treatment trials and biorepository studies. Enrollment in treatment trials was particularly high at National Cancer Institute-designated centers.
A Northwestern University study found ChatGPT's responses to radiation oncology patient questions were on par or exceeded professional society answers. The AI technology aims to empower patients before and after seeing physicians, while also reducing clinician burnout.
Researchers from the University of Southern Denmark have identified specific groups of cells driving resistance to chemotherapy in TNBC, offering new biomarkers and alternative treatment options. The studies shed light on the mechanisms behind chemoresistance and its epigenetic control.
A 10-center study found that microwave ablation is associated with similar progression-free survival rates to surgery but with fewer complications and a greater potential for preserving thyroid function. The procedure resulted in less blood loss, shorter incision length, and shorter procedure and hospitalization durations.
Researchers at Tel Aviv University developed a novel therapeutic strategy using existing medications to inhibit bone metastasis in breast cancer patients. The combination of drugs improved survival rates and reduced bone metastases in animal models and human tissue samples.
Researchers developed a novel assay to study immune checkpoint molecules in blood plasma, finding elevated concentrations in patients with immune-reactive tumors who were nonresponsive to PD-1/PD-L1 blockade therapy. Soluble factors correlated with exhausted antitumor immunity and predicted therapy efficacy.
A second-generation melanoma vaccine has shown improved survival rates for male patients compared to female patients, particularly those who are younger and have earlier-stage cancer. The vaccine targets helper T cells to recognize melanoma proteins, leading to boosted patient survival and reduced cancer reoccurrences.
A survey of 204 oncologists found that while patients should understand AI models, most agreed that patients should consent to their use. The study highlights the need for rigorous assessments of AI's impact on care decisions and patient autonomy.
A clinical trial from Keck Medicine of USC will investigate the feasibility of treating non-small cell lung cancer with immunotherapy provided at home. The study aims to enroll 37 patients and examine the safety, efficacy, and patient compliance with at-home treatment.
A nationwide study finds that individuals diagnosed with colon cancer who resided in previously redlined neighborhoods are more likely to be diagnosed with advanced-stage disease and have worse survival rates. The research highlights the long-lasting impact of institutional racism on access to quality cancer care.
A study published in the Journal of the American College of Surgeons found that hospitals accredited by the National Accreditation Program for Rectal Cancer (NAPRC) demonstrate significantly better outcomes for patients undergoing rectal cancer surgery. These institutions show lower rates of mortality, complications, and morbidity comp...
The study found that neoadjuvant chemotherapy increased median overall survival to 37 months and progression-free survival to 26 months. 57.2% of patients showed an objective response, with nearly one-fourth experiencing lymph-node pathologic complete response.
Researchers have identified a protein, NPEPPS, that enables cisplatin-resistant cancer cells to become responsive to treatment. This discovery could increase patient eligibility and make platinum-based therapies more effective.
Researchers assessed the feasibility of dual PD-L1/CTLA-4 checkpoint inhibition in Stage II or III hormone receptor-positive, HER2-negative breast cancer. Eight patients received upfront durvalumab and tremelimumab prior to neoadjuvant chemotherapy, showing mixed responses and limited benefit.
A new therapy combines gene-modified dendritic cells with immunotherapy to promote a stronger immune response against lung cancer. The treatment slows down tumor growth and activates T cells to attack cancer cells systemically.
A new analysis by researchers from Penn Medicine found that minority patients with lymphoma may be less likely to receive CAR T cell therapy due to clinical, provider, and socioeconomic barriers. The study assessed data from two cancer centers and found significant disparities in treatment access among minority populations.
Researchers present findings on immunotherapy approaches, a potential biomarker for neuroendocrine carcinomas, and improved treatments for pancreatic cancer and melanoma. A UCLA team identified UCHL1 as a molecular indicator and therapeutic target for aggressive neuroendocrine cancers.
The COVID-19 pandemic caused a significant decrease in colorectal cancer surgeries, with patients undergoing procedures having more advanced stages of cancer compared to those treated in 2019. The study found that approximately 10,000 fewer patients did not have surgery for colorectal cancer in 2020.
Primary care physicians struggle to balance harms and benefits of lung cancer screening in patients with multiple health issues, often relying on clinical judgment. Ultimately, the decision rests with the patient, who makes their own choice despite physician advice.
Researchers found no significant differences between standard and keyhole surgical incision types on short-term clinical outcomes, physical function recovery, or NHS resource costs for oesophageal cancer patients. The ROMIO study suggests that surgeons can maintain their preferred procedure type without compromising patient care.
A new study suggests that tailored treatment can predict the response of breast cancer patients to chemotherapy, allowing for safe omission of extensive lymph node removal. The MARI protocol showed a 95% overall survival rate and 89% disease-free survival rate in patients who achieved pathological complete response.
Researchers found that next-generation sequencing (NGS) identified more patients with microsatellite instability than immunohistochemistry (IHC), potentially leading to thousands of missed diagnoses and patients receiving incorrect treatment. NGS could guide the standard of care towards using this test method instead of IHC.
Researchers have developed a new tool to help clinics recruit patients from more communities by analyzing nearby hospitals serving diverse populations. The approach aims to increase accessibility and diversity in cancer trials, with the potential to improve patient outcomes.
A combined PET-MRI scan improved treatment outcomes for 57 out of 205 patients with early-stage breast cancer. The scan helped doctors spot signs of tumour spread, enabling alternative treatments such as chemotherapy or different surgical approaches.
A new AI tool can predict which breast cancer patients are at risk of chronic arm swelling after surgery and radiotherapy. The tool, developed by international researchers, uses machine learning algorithms to analyze patient data and provides easily understandable explanations for doctors and patients.
Adding ribociclib to hormone therapy improves invasive disease-free survival by 90.4% at three years, distant disease-free survival by 90.8%, and recurrence-free survival by 91.7%. The study found a 25% relative reduction in recurrence rate for patients with stage 2 or 3 HR-positive, HER2-negative early breast cancer.
Researchers have developed a vascularized organoid model (VOM) that accurately replicates the actual vasculature and environment of gastric cancer, enabling patient-specific predictions of response to anticancer drugs. The VOM demonstrates high cell viability rates and similarity to actual gastric cancer conditions.
Researchers found that young breast cancer patients who received a low-dose radiotherapy boost had a lower risk of local recurrence after 10 years, with only 4.4% experiencing recurrence. In contrast, high-dose boosts resulted in fewer recurrences but also more severe fibrosis and cosmetic issues.
A new genetic test has identified patients with triple negative early-stage breast cancer who are unlikely to respond to immunotherapy drugs. The test, called ImPrintTN, can predict a patient's likelihood of responding to these treatments and help avoid severe side effects.
Researchers identify mitochondrial priming as a key driver of multi-drug resistance in relapsed acute myeloid leukemia. A new technique called dynamic BH3 profiling reveals anti-cancer drugs capable of overcoming resistance.